Preoperative concurrent chemoradiotherapy for stages II–IV oral squamous cell carcinoma: a retrospective analysis and the future possibility of this treatment strategy

Kirita, Tadaaki; Yamanaka, Yasutsugu; Imai, Yumiko; Yamakawa, Nobuhiro; Aoki, Katsuya; Nakagawa, Yasuaki; Yagyuu, Takahiro; Hasegawa, Masatoshi

doi:10.1016/j.ijom.2011.12.003

Cited by 27 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preoperative chemoradiotherapy followed by surgery has become established in the clinical management of locally advanced operable OSCC over the last 20 years [4–9]. Most studies in the literature have used 40 or 50 Gy for preoperative radiotherapy, and cisplatin is often used as the radiosensitizing agent [4, 5, 7].…”

Section: Introductionmentioning

confidence: 99%

Multicenter phase II trial of preoperative chemoradiotherapy with S-1 for locally advanced oral squamous cell carcinoma

Harada

Omura

Tomioka

et al. 2013

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

PurposeWe evaluated whether preoperative chemotherapy with S-1 and concurrent radiotherapy is feasible and efficacious in the treatment of advanced oral squamous cell carcinoma.MethodsParticipants comprised 39 patients with oral carcinoma (stage III, n = 15; stage IVA, n = 24). All patients received a total radiation dose of 40 Gy, in once-daily 2-Gy fractions, and received S-1 at 65 mg/m2/day for 5 consecutive days, over 4 consecutive weeks with concurrent radiotherapy.ResultsHematological toxicity was mild and reversible. The most common non-hematological toxicity was grade 3 mucositis, but this was transient and tolerable. Radical surgery was performed for 37 patients, with the remaining 2 patients declining the surgery. Postoperatively, local failure developed in 1 patient, and neck failure in 2 patients. Distant metastases were identified in 4 patients. At a median follow-up of 38.0 months (range 23–88 months), locoregional control, disease-specific survival, and overall survival rates at 3 years were 91.5, 83.8, and 83.8 %, respectively.ConclusionConcurrent administration of S-1 and radiotherapy combined with surgery offers a well-tolerated method of successfully treating advanced oral squamous cell carcinoma. The locoregional control rate remains high even at 3 years of follow-up, and no serious adverse effects have been encountered.

show abstract

Section: Introductionmentioning

confidence: 99%

Multicenter phase II trial of preoperative chemoradiotherapy with S-1 for locally advanced oral squamous cell carcinoma

Harada

Omura

Tomioka

et al. 2013

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…It is clinically characterized by a high degree of malignancy, trend toward regional lymph node metastasis and poor prognosis (2). The majority of advanced OSCCs exhibit invasive growth (39), and it is difficult to surgically remove tumors that have infiltrated surrounding tissues and migrated distantly, and traditional chemotherapy has been demonstrated to have a low efficacy in this scenario (40). The improvement of early diagnosis and the implementation of individualized treatment has become necessary to ameliorate the treatment efficacy and prognosis of OSCC (41).…”

Section: Discussionmentioning

confidence: 99%

Elucidating the mechanism of miRNA-214 in the regulation of gingival carcinoma

Gong

Yang

Tian

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the present study was to evaluate the expression levels of microRNA (miRNA)-214 in tumor tissue, blood and saliva of patients with gingival carcinoma, and to investigate the mechanisms underlying the infiltration and invasion of gingival carcinoma. Between January 2013 and March 2015, blood and saliva samples, gingival carcinoma tumor specimens and peritumoral tumor tissues were harvested from 56 patients with gingival carcinoma. Blood and saliva samples were also harvested from 33 control patients without gingival carcinoma. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed to detect miRNA-214 and protein tyrosine phosphatase gene (PTEN) mRNA levels. Western blotting and ELISA were performed to detect PTEN protein levels. The results of RT-qPCR demonstrated that the expression of PTEN mRNA in tumor tissues, blood and saliva of patients with gingival carcinoma were significantly decreased compared with that of the control group (P<0.05). These findings were consistent were consistent with the results of PTEN protein expression detected via western blotting and ELISA in these samples (P<0.05). Conversely, the expression levels of miRNA-214 in these samples were significantly increased (P<0.05) in patients with gingival carcinoma compared with the control group. The decreased expression of PTEN may be associated with the expression of miRNA-214. miRNA-214 may regulate infiltration and invasion of gingival carcinoma via PTEN. These results suggest that miRNA-214 may be used as a marker of gingival carcinoma.

show abstract

“…Several studies have demonstrated that this treatment results in a higher overall survival rate in patients with OSCC (6)(7)(8)(9)(10)(22)(23)(24). The inclusion of pre-operative chemoradiotherapy is credited with this improvement in the overall survival rate.…”

Section: Discussionmentioning

confidence: 99%

“…Kirita et al has previously reported that pre-operative cisplatin (CDDP)-based intravenous chemotherapy and concurrent radiotherapy (total dose, 40 Gy) resulted in a clinical tumor response of 92.8% and a good prognosis, with a 79.3% 5-year overall survival rate, in Clinicopathological evaluation of pre-operative chemoradiotherapy with S-1 as a treatment for locally advanced oral squamous cell carcinoma SHINTARO patients with resectable advanced OSCC (10). Several studies have also demonstrated an improved 5-year survival rate subsequent to using this treatment in patients with advanced OSCC (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

“…Several studies have also demonstrated an improved 5-year survival rate subsequent to using this treatment in patients with advanced OSCC (7)(8)(9). Although the platinum-based chemotherapeutic regimens used in these protocols significantly improve local tumor control, adverse events, including nausea, vomiting, renal damage, anorexia and hematological toxicity, are severe issues (10). S-1 is an oral fluoropyrimidine preparation that consists of tegafur, the dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine and potassium oxonate, which inhibits orotate phosphoribosyl transferase in the gastrointestinal tract, thereby reducing the gastrointestinal toxicity of 5-fluorouracil (11).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological evaluation of pre-operative chemoradiotherapy with S-1 as a treatment for locally advanced oral squamous cell carcinoma

et al. 2016

View full text Add to dashboard Cite

Abstract. The administration of pre-operative chemotherapy with S-1 and concurrent radiotherapy at a total dose of 30 Gy was clinicopathologically evaluated as a treatment for locally advanced oral squamous cell carcinoma (OSCC) in the present study. The participants comprised 81 patients with OSCC, consisting of 29 patients with stage II disease, 12 patients with stage III disease and 40 patients with stage IV disease. All patients received a total radiation dose of 30 Gy in daily fractions of 2 Gy, 5 times a week, for 3 weeks, and the patients were concurrently administered S-1 at a dose of 80-120 mg, twice daily, over 4 consecutive weeks. Radical surgery was performed in all cases at 2-6 weeks subsequent to the end of pre-operative chemoradiotherapy. The most common adverse event was oropharyngeal mucositis, but this was transient in all patients. No severe hematological or non-hematological toxicities were observed. The clinical and histopathological response rates were 70.4 and 75.3%, respectively. Post-operatively, local failure developed in 6 patients (7.4%) and neck failure developed in 2 patients (2.5%). Distant metastases were found in 7 patients (8.6%). The overall survival rate, disease-specific survival rate and locoregional control rate at 5 years were 87.7, 89.9 and 90.6%, respectively. Locoregional recurrence occurred more frequently in patients that demonstrated a poor histopathological response compared with patients that demonstrated a good response (P<0.01). These results indicate that pre-operative S-1 chemotherapy with radiotherapy at a total dose of 30 Gy is feasible and effective for patients with locally advanced OSCC, and that little or no histopathological response may be a risk factor for locoregional recurrence in this treatment. IntroductionOral squamous cell carcinoma (OSCC) accounts for ~3% of all malignancies worldwide (1). Despite this low frequency of occurrence, the 5-year overall survival rate of patients with OSCC has not exceeded 55% over the previous decade, due to the local aggressiveness and high recurrence rate of the disease (2). Advanced OSCC remains refractory and results in mortality in >50% of cases (1).Complete locoregional control is crucial in the treatment of OSCC, as distant metastases are rarely identified at the initial presentation (3). Therefore, multimodal treatment has typically been implemented for advanced OSCC in order to control locoregional disease, generally consisting of radical surgery followed by radiotherapy (4). The issue with this combined therapeutic approach is the high recurrence rate at primary or regional sites within the first 2 years subsequent to treatment (5). As a result, 5-year survival rates have been low in patients treated with this therapy (5).Pre-operative chemoradiotherapy has become an established component of the clinical management of locoregionally advanced operable OSCC (6-10). Kirita et al has previously reported that pre-operative cisplatin (CDDP)-based intravenous chemotherapy and concurrent radiotherapy (total dose, ...

show abstract

Preoperative concurrent chemoradiotherapy for stages II–IV oral squamous cell carcinoma: a retrospective analysis and the future possibility of this treatment strategy

Cited by 27 publications

References 26 publications

Multicenter phase II trial of preoperative chemoradiotherapy with S-1 for locally advanced oral squamous cell carcinoma

Multicenter phase II trial of preoperative chemoradiotherapy with S-1 for locally advanced oral squamous cell carcinoma

Elucidating the mechanism of miRNA-214 in the regulation of gingival carcinoma

Clinicopathological evaluation of pre-operative chemoradiotherapy with S-1 as a treatment for locally advanced oral squamous cell carcinoma

Contact Info

Product

Resources

About